Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 10 recruiting now early-phase tilt small index

CRC, Colorectal Cancer: early-phase trial registry

10 of 11 indexed CRC, Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 10 currently recruiting · #1,577 of 28,707 conditions by registered trial count

CRC, Colorectal Cancer: 11 US clinical trials tracked, 10 recruiting.

CRC, Colorectal Cancer is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 2 of these trials.

Enrollment posture brief

Registry condition crc-colorectal-cancer

OPEN 10 | RECR 91% | LATE 1 | EARLY 7 | RANK #1577 | SPON 2

Nearest open-share peer: Depression Disorders (91% recruiting · 11 trials)

CRC, Colorectal Cancer (this)91%Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near CRC, Colorectal Cancer

CRC, Colorectal Cancer lists 10 open slots (91% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for CRC, Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. CRC, Colorectal Cancer is recruiting above its size-band peers.

    10 of 11 indexed trials (90.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates CRC, Colorectal Cancer research.

    City of Hope Medical Center accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Typical CRC, Colorectal Cancer enrolment sits around 170 participants.

    Median target enrolment is 170 among the 11 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.

  4. CRC, Colorectal Cancer research is mostly interventional.

    9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 21Phase 31

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 3 700 participants

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Incyte Corporation

NCT07284849

RECRUITING 600 participants

cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer

City of Hope Medical Center

NCT07224815

RECRUITING 500 participants

Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

City of Hope Medical Center

NCT07224841

RECRUITING Phase 1 387 participants

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

NCT06917079

RECRUITING Phase 1 188 participants

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Alterome Therapeutics

NCT06835569

RECRUITING Phase 1 170 participants

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Oncology

NCT07085091

RECRUITING NA 150 participants

Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma

University of Oklahoma

NCT07254910

RECRUITING Phase 2 136 participants

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

NGM Biopharmaceuticals

NCT07033026

RECRUITING Phase 1 130 participants

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Sairopa B.V.

NCT05856981

RECRUITING Phase 1 128 participants

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Kumquat Biosciences

NCT06720987

ACTIVE NOT RECRUITING Phase 1 120 participants

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Indaptus Therapeutics

NCT05651022

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on CRC, Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cetuximab Drug
2 trials
Pembrolizumab Drug
2 trials
Decoy20 Drug
1 trials
Placebo given Drug
1 trials
NGM120 Q8W Drug
1 trials
NGM120 Q4W Drug
1 trials
KQB365 Drug
1 trials
ALX2004 Drug
1 trials

US sites by state

Facility locations filed on CRC, Colorectal Cancer trials. A trial with sites in several states counts in each.

Texas 5 trials
Florida 5 trials
California 5 trials
Virginia 4 trials
Michigan 4 trials
Ohio 3 trials
New York 3 trials
Massachusetts 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this CRC, Colorectal Cancer page

11 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CRC, Colorectal Cancer condition card totals 11 registered trials; most-linked intervention Cetuximab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.